Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. cut its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 26.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 267,037 shares of the biotechnology company's stock after selling 95,974 shares during the quarter. Principal Financial Group Inc. owned 0.28% of Sarepta Therapeutics worth $33,350,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Capital International Investors raised its holdings in Sarepta Therapeutics by 1.6% during the 1st quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company's stock worth $623,676,000 after purchasing an additional 76,032 shares during the last quarter. Farallon Capital Management LLC boosted its stake in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company's stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the last quarter. Thrivent Financial for Lutherans grew its holdings in Sarepta Therapeutics by 6.3% during the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company's stock worth $101,858,000 after buying an additional 37,940 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Sarepta Therapeutics by 26.3% during the first quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company's stock valued at $75,040,000 after purchasing an additional 120,535 shares in the last quarter. Finally, abrdn plc grew its holdings in shares of Sarepta Therapeutics by 30.7% in the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company's stock valued at $53,935,000 after acquiring an additional 101,253 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Insiders Place Their Bets

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Sarepta Therapeutics news, Director Michael Andrew Chambers bought 37,038 shares of the business's stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the transaction, the director now owns 284,034 shares of the company's stock, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SRPT shares. Barclays cut their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating for the company in a research note on Thursday, August 8th. Jefferies Financial Group started coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a "buy" rating and a $165.00 price objective for the company. Citigroup dropped their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating on the stock in a research report on Thursday, August 8th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Finally, Robert W. Baird cut their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $181.33.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded down $3.34 during trading on Tuesday, reaching $114.50. The stock had a trading volume of 677,876 shares, compared to its average volume of 1,231,382. The business has a fifty day moving average price of $125.56 and a 200-day moving average price of $132.90. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.19 and a current ratio of 3.84. The stock has a market cap of $10.94 billion, a PE ratio of 94.27 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1-year low of $76.61 and a 1-year high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.